Clinical Trials Directory

Trials / Completed

CompletedNCT03031626

Oxygen Versus Medical Air for Treatment of CSA in Prader Will Syndrome

Comparison of Therapeutic Oxygen Versus Medical Air for the Treatment of Central Sleep Apnea in Infants and Children With Prader Willi Syndrome: A Proof of Concept Study

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
9 (actual)
Sponsor
The Hospital for Sick Children · Academic / Other
Sex
All
Age
2 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to determine if treatment with Medical Air (21% oxygen in room air) compared to supplemental oxygen (100% oxygen) will lead to similar improvements in the central apnea-hypopnea index (CAHI) for infants with Prader-Willi Syndrome. Despite the vast amount of research investigating the cause of central sleep apnea, there remain gaps in knowledge, lending to further research efforts. The decision to compare oxygen to medical air is based on several theorized mechanisms. The first of which is the supposition that provision of medical air may act as an arousal stimulus for the hypothalamus, thereby preventing sleep disordered breathing. Secondly, the hypercapnic challenge performed by Livingston et al demonstrated a delayed hypercapneic arousal response in PWS subjects despite simultaneous hyperoxia, leading us to question if therapeutic oxygen really plays a significant role in treating CSA. Lastly, the delivery of medical air via nasal prongs may provide sufficient arousal to terminate the cycle of events leading to central apnea, as described by Urquhart et al. A deeper understanding of central sleep apnea is essential to ameliorating its adverse sequelae, which include symptoms of ADHD, impaired attention, behavioral problems, and academic difficulties.

Conditions

Interventions

TypeNameDescription
BIOLOGICALMedical Air vs OxygenMedical Air/Oxygen will be given

Timeline

Start date
2016-09-01
Primary completion
2025-03-15
Completion
2025-03-15
First posted
2017-01-25
Last updated
2025-06-08

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT03031626. Inclusion in this directory is not an endorsement.